A detailed history of Long Focus Capital Management, LLC transactions in Insmed Inc stock. As of the latest transaction made, Long Focus Capital Management, LLC holds 628,900 shares of INSM stock, worth $46.2 Million. This represents 1.68% of its overall portfolio holdings.

Number of Shares
628,900
Previous 740,900 15.12%
Holding current value
$46.2 Million
Previous $49.6 Million 7.52%
% of portfolio
1.68%
Previous 1.99%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$62.0 - $79.01 $6.94 Million - $8.85 Million
-112,000 Reduced 15.12%
628,900 $45.9 Million
Q2 2024

Aug 13, 2024

BUY
$22.0 - $69.71 $6.8 Million - $21.6 Million
309,251 Added 71.64%
740,900 $49.6 Million
Q1 2024

May 14, 2024

BUY
$25.72 - $29.94 $1.54 Million - $1.8 Million
60,000 Added 16.14%
431,649 $11.7 Million
Q2 2023

Aug 14, 2023

BUY
$16.44 - $21.1 $164,400 - $211,000
10,000 Added 2.77%
371,649 $7.84 Million
Q1 2023

May 17, 2023

BUY
$16.26 - $21.73 $2.38 Million - $3.19 Million
146,592 Added 68.16%
361,649 $6.17 Million
Q1 2023

May 12, 2023

SELL
$16.26 - $21.73 $1.79 Million - $2.39 Million
-109,943 Reduced 33.83%
215,057 $3.67 Million
Q4 2022

Feb 13, 2023

BUY
$16.98 - $23.15 $933,900 - $1.27 Million
55,000 Added 20.37%
325,000 $6.49 Million
Q3 2022

Nov 14, 2022

BUY
$20.88 - $28.21 $417,600 - $564,200
20,000 Added 8.0%
270,000 $5.82 Million
Q2 2022

Aug 12, 2022

BUY
$17.07 - $25.71 $1.54 Million - $2.31 Million
90,000 Added 56.25%
250,000 $4.93 Million
Q1 2022

May 13, 2022

BUY
$20.42 - $28.13 $1.63 Million - $2.25 Million
80,000 Added 100.0%
160,000 $3.76 Million
Q4 2021

Feb 14, 2022

BUY
$25.89 - $33.45 $2.07 Million - $2.68 Million
80,000 New
80,000 $2.18 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.94B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Long Focus Capital Management, LLC Portfolio

Follow Long Focus Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Long Focus Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Long Focus Capital Management, LLC with notifications on news.